Free Trial
NASDAQ:SRRK

Scholar Rock Q1 2024 Earnings Report

Scholar Rock logo
$31.95 +0.55 (+1.75%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$32.78 +0.82 (+2.58%)
As of 08/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scholar Rock EPS Results

Actual EPS
-$0.59
Consensus EPS
-$0.48
Beat/Miss
Missed by -$0.11
One Year Ago EPS
-$0.46

Scholar Rock Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scholar Rock Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Tuesday, May 7, 2024
Conference Call Time
7:00AM ET

Scholar Rock Earnings Headlines

Scholar Rock (NASDAQ:SRRK) Trading Down 10.2% on Disappointing Earnings
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Magnificent Seven—seven stocks he believes could deliver similar gains in under six years. His full breakdown is now live.
Scholar Rock (NASDAQ:SRRK) Shares Gap Down on Disappointing Earnings
See More Scholar Rock Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scholar Rock? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scholar Rock and other key companies, straight to your email.

About Scholar Rock

Scholar Rock (NASDAQ:SRRK), a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

View Scholar Rock Profile

More Earnings Resources from MarketBeat